Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostics and therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, and ophthalmological disorders. The companys diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimers disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation.
Its therapeutic products in development comprise Eltoprazine, a small molecule drug that is in Phase II clinical trials for the treatment of Parkinsons disease Levadopa-Induced Dyskinesia and adult attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including iretinitis pigmentosa, Parkinsons disease, cardiac ischemia, and stroke.
It is also developing NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinsons disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University to develop its full thickness skin replacement product. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.